Commitments and Contingencies (Details Narrative) - USD ($)				1 Months Ended									6 Months Ended	12 Months Ended
	May 06, 2020	Dec. 03, 2019	Dec. 03, 2018	Jun. 03, 2020	Mar. 03, 2020	Feb. 18, 2020	Nov. 27, 2019	Nov. 24, 2019	Nov. 22, 2019	May 31, 2019	Aug. 22, 2017	Dec. 31, 2011	Jan. 18, 2017	Jul. 31, 2020	Jul. 31, 2019	May 04, 2020	Apr. 09, 2020	Apr. 30, 2019	Feb. 28, 2019	Jan. 24, 2019	Jan. 07, 2019	Oct. 26, 2018
Commitments and Contingencies											The letter from AEXG counsel claimed that Generex’s acceptance of $3,000,000 in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs.
Litigation awards for damages			$ 315,695
Litigation awards, exercisable shares			84,000
Exercise price			$ 2.50
Note amount										$ 2,000,000					$ 446,600	$ 150,000	$ 50,000	$ 1,060,000	$ 1,500,000	$ 530,000		$ 682,000
Liquidated damages			$ 210,000
Legal fees			93,304
Legal cost			$ 12,393
Purchase price																						550,000
Debt issuance discount																						$ 122,000
Shares issued for acquisition, value														$ 1,151,952
Business acquisition, consideration transferred													$ 1,350,916
Total Fair Value of Assets Acquired																					$ 1,259,447
Research and development														2,106,364	1,748,882
Interest expenses														7,103,680	7,087,502
Accrued interest														3,911,141	3,055,945
Clinical trial agreement
Research and development														272,063
Master Services Agreement
Cost of agrrement					$ 300,000
Payment for services					$ 150,000
Laboratory Services Agreement
Payment for fees				$ 4,697
Cost of agrrement				$ 939,478
Forbearance Agreement.
Interest expenses														855,196	715,275
Accrued interest														3,911,141	$ 3,055,945
Olaregen
Intellectual property acquired							$ 650,000
Olaregen | Stock Purchase Agreement
Shares issued for acquisition, shares								4,250,000		4,000,000
Business acquisition, consideration transferred								$ 11,600,000
ALTuCELL
Due from related party														212,000
ALTuCELL | Stock Purchase Agreement
Shares issued for acquisition, shares									2,240,000
Shares issued for acquisition, value									$ 4,000,000
Business acquisition, consideration transferred									212,000
Total Fair Value of Assets Acquired									$ 3,500,000
Alternative Execution Group [Member]
Memorandum of Understanding description			The petition includes a demand of $3,300,360 as the value of the warrants. The arbitrator did not award the specific amount of $3.5 million, but only liquidated damages in the amount of $210,000 and the value of 84,000 warrants “as of today” (the date of the award) plus attorney’s fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees.
KSKZ Management, LLC
Value of damages sought		$ 3,450,000
Discover Growth Fund, LLC
Value of damages sought						$ 2,475,000
Litigation awards for damages						$ 2,200,000
Iliad Research and Trading
Shares issued for damages	3,499,415
Stock payable														1,459,676
Travis Bird Consulting Agreement
Consulting fees														1,404,915
Payment for fees														773,366
Accrued consulting fees														$ 631,549
Damages for Unpaid Invoices
Value of damages sought												$ 429,000
Lawsuit filing date												31-Dec-11
Name of Plaintiff												Vendor
Interest per annum, failure to pay settlement												3.00%
Fixed cost per annum, failure to pay settlement												$ 25,000
Breach of contract and detinue
Counterclaim proceeding												$ 200,000